期刊文献+

补肾醒脑方对拟血管性痴呆大鼠行为学及组织内胆碱乙酰转移酶含量的影响 被引量:7

The Effect of Bushen Xingnao(BSXN)Prescription on Rats' Bethavior with Vascular Dementia and the Contents of Choline Acetyltransferase in Its Hippocampus Tissue
下载PDF
导出
摘要 目的:观察补肾醒脑方对血管性痴呆(VD)模型大鼠海马组织胆碱乙酰转移酶(ChAT)与学习记忆功能的影响。方法:双侧颈总动脉结扎并反复缺血再灌注法制模,将大鼠分为模型组、西药组和中药组,进行药物治疗。用跳台试验检测大鼠行为学变化,用酶免法检测血清和海马组织ChAT含量。结果:补肾醒脑方组大鼠跳台检测反应期比模型组缩短(P<0.05);中药组血清和海马ChAT含量比模型组增加(P<0.05)。结论:对血管性痴呆大鼠血清和海马内ChAT含量的改善是补肾醒脑方治疗获效的机制之一。 Objective:To observe the pathology mechanism of vascular dementia(VD) rats by using Bushen Xingnao(BSXN) prescription and study the effect between hippocampal organization choline acetyltransterase(ChAT) and the function of learning and memory.Method:The VD model rats are induced by ligating two sides of the total artery in neck,repeatedly use ischemia-reperfusion method to make the models.The models are randomly divided into Chinese medicine group(CG),western medicine group(WG),model group(WG),given drug treatment.Observe VD rat models behavioral changes through using the diving platform experiment,and detect the ChAT content in serum and hippocampal organization.Results The escape latency(EL) of CG was obviously shorter than that of MG.The ChAT content of CG in serum and hippocampal organization was higher than that of MG(P<0.05).Conclusion:BSXN prescription can improve the content of ChAT in serum and hippocampal organization,which may play a key role in onset and development of VD.
出处 《中医药学报》 CAS 2011年第4期21-23,共3页 Acta Chinese Medicine and Pharmacology
基金 黑龙江省中医药科研项目(编号:ZH10-W97) 牡丹江医学院科研课题(编号:B200815)
关键词 血管性痴呆 补肾醒脑方 行为学 胆碱乙酰转移酶 Vascular dementia Bushen Xingnao prescription Behavior Choline acetyltransferase
  • 相关文献

参考文献7

二级参考文献29

  • 1王四平,郝宪恩,王鑫国,徐华洲,王菊素,李士懋.软脉胶囊含药血清对PC12细胞损伤的保护作用[J].中国老年学杂志,2005,25(1):87-89. 被引量:4
  • 2刘金,杨万章.血管性痴呆的中西医治疗临床研究进展[J].中西医结合心脑血管病杂志,2005,3(4):338-340. 被引量:9
  • 3樊敬峰,宋春风,吕佩源,尹昱,王伟斌,梁翠萍.血管性痴呆小鼠海马胆碱乙酰转移酶和其mRNA变化特征及喜得镇的影响[J].中国老年学杂志,2005,25(6):677-679. 被引量:5
  • 4Grantham C,Geerts H.The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease[J].J Neurol Sci,2002;203(1):131-6.
  • 5Erkinjuntti T.Cognitive decline and treatment options for patients with vascular dementia[J].Acta Neurol Scand Suppl,2002;178(1):15-8.
  • 6Marmigere F,Rage F,Tapia-Arancibia L.Regulation of brain-derived neurotrophic factor transcripts by neuronal activation in rat hypothalamic neurons[J].Neurosci Res,2001;66(3):377-89.
  • 7Kawano H,Uede K,Hasuo Y.Prevalence of dementia and evaluation of its clinical diagnosis during 3-year follow-up study in Japanese community[J].Stroke,1990;21(suppl):1-35.
  • 8Corey-Bloom J,Thal LJ,Galasko D,et al.Diagnosis and evaluation of dementia[J].Neurology,1995;45(2):211-8.
  • 9Ishimaru H,Talahashi A,Ikarashi Y,et al.NGF delays rather than prevents the cholinergic terminal damage and delayed neuronal death in the hippocampus after ischemia[J].Brain Res,1998;789(2):194-201.
  • 10Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: Diagnostic criteria for research studies - Report of the NINDS - AIREN International Workshop [J] . Neurology, 1993 (43) :250 - 260.

共引文献58

同被引文献156

引证文献7

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部